FDA 483 - Vijay Swarup MD - May 30, 2025

An FDA inspection of Vijendra Swarup, MD in Phoenix, AZ, a clinical investigator, revealed two significant observations. The firm failed to promptly report serious adverse events to the sponsor and did not conduct an investigation in accordance with the investigational plan, specifically regarding the timely sign-off of screening labs prior to subject randomization.